Exciting News from HT-Advance! PREDICT study

Exciting News from HT-Advance! 

We’re thrilled to announce that the first patient had been included in the HT-PREDICT study end of May 2024, marking a significant milestone for our consortium. 🌟

Radboudumc has led the way by successfully enrolling the first patient, setting the stage for a promising journey ahead. A special shoutout to @Joost Rutten, PI of the HT-PREDICT study, and Wendy van Haaren-Vorstenbosch Haaren for their dedication in conducting the screening visit with the patient.

As many of you know, patient recruitment can be one of the most challenging aspects of research. However, through our collaboration with Henk Schers and the Radboudumc Academisch Huisartsen Netwerk (AHN), we’ve been able to tap into primary care resources, ensuring access to patients with primary hypertension without extensive health problems. A huge thank you to everyone involved for their invaluable contributions and support.

photo by Teun Keijzer